Anette Nieves, MD
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.9% of the total across 449 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,899, more than ten times the $242 reported in 2019.
Across 449 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- F. Hoffmann-la Roche AG$1K
- Teva Pharmaceuticals USA, Inc.$948
- Eisai Inc.$816
- Acadia Pharmaceuticals Inc$772
- Neurocrine Biosciences, Inc.$586
- plus $3K from 30 others
Across 471 payments — averaging $20,768 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$3.8M
- Genentech, Inc.$2.9M
- Eli Lilly$1.5M
- Eisai Inc.$640K
- UCB SA$450K
- AbbVie$272K
- plus $192K from 7 others
What the payments were for
- Consulting fees$6487%
- Food & beverage$8,79392%
- Education$1301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 93 | $2,135 |
| F. Hoffmann-la Roche AG | 2 | $1,200 |
| Teva Pharmaceuticals USA, Inc. | 78 | $948 |
| Eisai Inc. | 38 | $816 |
| Acadia Pharmaceuticals Inc | 47 | $772 |
| Neurocrine Biosciences, Inc. | 30 | $586 |
| MDD US Operations, LLC | 25 | $429 |
| Amneal Pharmaceuticals LLC | 21 | $390 |
| Otsuka America Pharmaceutical, Inc. | 15 | $313 |
| Boston Scientific | 10 | $306 |
| Lundbeck LLC | 11 | $232 |
| Kyowa Kirin, Inc. | 8 | $178 |
| Supernus Pharmaceuticals, Inc. | 14 | $170 |
| GE HealthCare | 5 | $122 |
| Merz Pharmaceuticals, LLC | 5 | $116 |
| Argenx US, Inc. | 5 | $100 |
| Corium, LLC | 3 | $97 |
| Avion Pharmaceuticals | 4 | $64 |
| Lilly USA, LLC | 3 | $62 |
| Idorsia Pharmaceuticals US Inc | 4 | $61 |
| UCB, Inc. | 4 | $61 |
| Axsome Therapeutics, Inc. | 3 | $54 |
| C2n Diagnostics, LLC | 3 | $54 |
| Arbor Pharmaceuticals, Inc. | 3 | $38 |
| Adamas Pharmaceuticals, Inc. | 3 | $37 |
| Medtronic | 1 | $36 |
| Cala Health, Inc. | 2 | $36 |
| Life Molecular Imaging Ltd | 1 | $26 |
| Abbott | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Revance Therapeutics, Inc. | 1 | $17 |
| Biogen | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Acorda Therapeutics, Inc | 1 | $15 |
| Insightec,inc | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,571 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ApokynApomorphine Hcl | 17 | $639,230 |
| NuplazidPimavanserin Tartrate | 46 | $230,802 |
| RytaryCarbidopa/Levodopa | 120 | $190,306 |
| GocovriAmantadine Hcl | 38 | $120,295 |
| NourianzIstradefylline | 13 | $41,226 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 1,023 | $40,719 |
| Droxidopa | 12 | $35,865 |
| Memantine Hcl | 688 | $26,439 |
| NeuproRotigotine | 18 | $23,250 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 469 | $21,494 |
| BotoxOnabotulinumtoxina | 19 | $16,425 |
| NamzaricMemantine Hcl/Donepezil Hcl | 11 | $12,455 |
| AmantadineAmantadine Hcl | 161 | $11,101 |
| MyrbetriqMirabegron | 14 | $10,993 |
| Ropinirole ErRopinirole Hcl | 25 | $9,939 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $772 | $230,80246 claims |
| Amneal Pharmaceuticals LLCRytary | $390 | $190,306120 claims |
| MDD US Operations, LLCGocovri | $429 | $120,29538 claims |
| Kyowa Kirin, Inc.Nourianz | $178 | $41,22613 claims |
| AbbVieBotox, Namzaric | $2,135 | $28,87930 claims |
| UCB, Inc.Neupro | $61 | $23,25018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,434 neurology providers in Florida.
Other neurology in Ocala
- Lance KimOcala$1M
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Tuan VuTampa$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.